WATERTOWN, Mass., May possibly 20, 2021 (Globe NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical corporation groundbreaking a new class of little-molecule medications that selectively damage disorder-triggering proteins as a result of degradation, today declared the appointment of Lauren White to the job of chief money officer, powerful June 21, 2021. Ms. White’s appointment will initiate William (Monthly bill) McKee’s planned changeover from interim main money officer, a role he has held since March 31, 2020. Mr. McKee will continue to be engaged to assist C4T in a aspect-time consulting capacity to guarantee a sleek transition.
“As we continue to advance our portfolio of novel protein degraders, we are delighted to welcome Lauren to our workforce. Her established track report of strategically allocating resources throughout research and early-phase clinical progress packages, as well as her activities in economic reporting and accounting, will be a must have as we keep on to create C4T and do the job to change client treatment,” claimed Andrew Hirsch, president and chief govt officer of C4 Therapeutics. “In addition, we are exceptionally grateful for Bill’s contributions in shepherding C4T by our Sequence B funding and first community presenting and in creating a foundational money framework for C4T as a general public corporation.”
Ms. White joins C4 Therapeutics with over 20 many years of intercontinental working experience in company finance and strategy. She is signing up for from Novartis, exactly where she held roles of expanding responsibility in the world-wide finance corporation. Most lately, she served as vice president and world-wide head of business preparing and evaluation at Novartis Institutes for BioMedical Study (NIBR), the place she led strategic economic assignments for the world wide investigation device. At Novartis, Ms. White also launched the worldwide health and fitness company unit as chief economic officer immediately after serving in roles across worldwide finance and money reporting and accounting. Previously in her career, Ms. White labored in technique and advertising roles with Boston Consulting Team and Standard Electric powered. Ms. White acquired an M.B.A. from Harvard Business enterprise College and a B.S. from the Carroll College of Management at Boston Higher education.
“I am thrilled to sign up for C4 Therapeutics at a pivotal time in the Company’s enhancement, as it prepares to initiate its to start with clinical demo and progress a novel portfolio of targeted protein degraders for the profit of individuals,” stated Ms. White. “Targeted protein degradation gives unique rewards about classic smaller molecule approaches and I imagine C4T’s impressive drug discovery engine has immense likely throughout a vary of oncology indications. I seem forward to working with the group toward our shared mission of reworking individual cure by way of specific protein degradation.”
About C4 Therapeutics
C4 Therapeutics (C4T) is a biopharmaceutical firm centered on harnessing the body’s organic regulation of protein levels to build novel therapeutic candidates to goal and demolish illness-triggering proteins for the remedy of cancer and other health conditions. This focused protein degradation method gives rewards more than regular therapies, like the likely to handle a wider variety of health conditions, reduce drug resistance, realize better efficiency, and lower facet effects by means of bigger selectivity. To master far more about C4 Therapeutics, check out www.C4Therapeutics.com.
Forward-Looking Statements
This press release is made up of “forward-seeking statements” of C4 Therapeutics, Inc. in the indicating of the Personal Securities Litigation Reform Act of 1995. These forward-seeking statements may consist of, but may well not be confined to, categorical or implied statements with regards to our skill to develop potential therapies for sufferers the design and likely efficacy of our therapeutic strategies the predictive ability of our TORPEDO™ system in the improvement of novel, selective, orally bioavailable degraders the potential timing, design and style and improvement of our preclinical reports and scientific trials, together with the possible timing for regulatory authorization relevant to medical trials our means and the possible to efficiently manufacture and provide our merchandise candidates for scientific trials our means to replicate effects accomplished in our preclinical scientific studies or medical trials in any potential scientific studies or trials our recent methods and hard cash runway and regulatory developments in the United States and foreign international locations. Any ahead-hunting statements in this push release are based on management’s recent anticipations and beliefs of long run situations and are subject matter to a amount of dangers and uncertainties that could induce actual final results to differ materially and adversely from those set forth in or implied by such ahead-wanting statements. These hazards and uncertainties contain, but are not minimal to: uncertainties related to the initiation, timing, development and conduct of preclinical and scientific experiments and other development requirements for our merchandise candidates the danger that any 1 or far more of our merchandise candidates will price additional to develop or might not be efficiently formulated and commercialized and the risk that the effects of preclinical research and/or medical trials will or will not be predictive of potential benefits in connection with foreseeable future studies or trials. For a discussion of these and other hazards and uncertainties, and other important components, any of which could result in our real final results to vary from people contained in the ahead-searching statements, see the area entitled “Risk Factors” in C4 Therapeutics’ most modern Annual Report on Variety 10-K and/or Quarterly Report on Variety 10-Q, as filed with the Securities and Exchange Fee. All facts in this press launch is as of the day of the launch, and C4 Therapeutics undertakes no obligation to update this data except necessary by regulation.
Make contact with: Trader Get in touch with: Kendra Adams SVP, Communications & Trader Relations [email protected] Media Make contact with: Loraine Spreen Director, Company Communications & Patient Advocacy [email protected]
